CY2022015I2 - Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι - Google Patents
Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοιInfo
- Publication number
- CY2022015I2 CY2022015I2 CY2022015C CY2022015C CY2022015I2 CY 2022015 I2 CY2022015 I2 CY 2022015I2 CY 2022015 C CY2022015 C CY 2022015C CY 2022015 C CY2022015 C CY 2022015C CY 2022015 I2 CY2022015 I2 CY 2022015I2
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- long
- related compositions
- compstatin analogs
- acting compstatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727094P | 2012-11-15 | 2012-11-15 | |
| US201261727093P | 2012-11-15 | 2012-11-15 | |
| PCT/US2013/070417 WO2014078731A2 (en) | 2012-11-15 | 2013-11-15 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| EP13854990.2A EP2920201B1 (en) | 2012-11-15 | 2013-11-15 | Long-acting compstatin analogs and related compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2022015I1 CY2022015I1 (el) | 2023-01-05 |
| CY2022015I2 true CY2022015I2 (el) | 2023-01-05 |
Family
ID=50731834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2022015C CY2022015I2 (el) | 2012-11-15 | 2022-06-09 | Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι |
Country Status (3)
| Country | Link |
|---|---|
| US (3) | US20160194359A1 (el) |
| CY (1) | CY2022015I2 (el) |
| WO (1) | WO2014078734A2 (el) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| MX356528B (es) | 2011-05-11 | 2018-06-01 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos. |
| MX366404B (es) | 2012-11-15 | 2019-07-08 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados. |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| US11903994B2 (en) * | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| RU2019113301A (ru) | 2016-10-17 | 2020-11-17 | Апеллис Фармасьютикалс, Инк. | Комбинированная терапия для ингибирования с3 |
| KR20180091773A (ko) * | 2017-02-07 | 2018-08-16 | 한미약품 주식회사 | 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법 |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| IL269844B2 (en) | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| RU2020128624A (ru) * | 2018-02-27 | 2022-03-28 | Зп Спв 3 К/С | Аналоги компстатина и их медицинское применение |
| EP4011905A3 (en) | 2018-04-06 | 2022-06-29 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with increased solubility and improved pharmacokinetic properties |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ, インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
| WO2020131974A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| US12312607B2 (en) * | 2019-05-24 | 2025-05-27 | Avitide LLC | AAV9 affinity agents |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| EP4398926A4 (en) * | 2021-09-09 | 2025-07-02 | Apellis Pharmaceuticals Inc | TREATMENT OF GEOGRAPHIC ATROPHY |
| TWI818431B (zh) * | 2022-02-08 | 2023-10-11 | 高雄醫學大學 | 雙環壬炔衍生物及其製備方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1549333E (pt) * | 2002-09-20 | 2012-01-03 | Univ Pennsylvania | Análogos de compstatina com actividade melhorada |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| CN102977191B (zh) * | 2005-11-28 | 2016-08-10 | 宾夕法尼亚州大学理事会 | 有效的c3补体抑制素类似物 |
-
2013
- 2013-11-15 WO PCT/US2013/070424 patent/WO2014078734A2/en not_active Ceased
- 2013-11-15 US US14/443,200 patent/US20160194359A1/en not_active Abandoned
-
2017
- 2017-04-12 US US15/485,706 patent/US20170283461A1/en not_active Abandoned
-
2019
- 2019-10-18 US US16/657,943 patent/US20200325175A1/en not_active Abandoned
-
2022
- 2022-06-09 CY CY2022015C patent/CY2022015I2/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160194359A1 (en) | 2016-07-07 |
| CY2022015I1 (el) | 2023-01-05 |
| US20170283461A1 (en) | 2017-10-05 |
| WO2014078734A2 (en) | 2014-05-22 |
| US20200325175A1 (en) | 2020-10-15 |
| WO2014078734A3 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2022015I1 (el) | Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι | |
| HUS2200026I1 (hu) | Hosszan ható compstatin-analógok és kapcsolódó készítmények, valamint módszerek | |
| FR24C1043I2 (fr) | Analogues du glucagon | |
| SMT202100154T1 (it) | Composizioni e metodi per identificare precisamente mutazioni | |
| LT3725778T (lt) | Enzalutamido kompozicijos | |
| LT2791160T (lt) | Modifikuotos mrnr sudėtys | |
| EP2787837A4 (en) | COMMONLY DECOMPOSED STABILIZER COMPOSITION | |
| BR112014032798A2 (pt) | composição | |
| DK2931970T4 (da) | Cellulose-afledte sammensætninger | |
| DK2841054T3 (da) | Injicerbart præparat | |
| ME03413B (me) | Kompozicije које sadrže peg i askorbat | |
| IL237914A0 (en) | Benzamides | |
| DK2844309T3 (da) | Selektivt polymeriserbare sammensætninger | |
| DK2868318T3 (da) | Injicerbar formulering | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| DK2877155T3 (da) | Opioidformuleringer | |
| PT2836483T (pt) | Agentes antimalária | |
| FR2988426B1 (fr) | Plate-forme inter-aubes | |
| FR2988427B1 (fr) | Plate-forme inter-aubes | |
| BR112014032712A2 (pt) | composição | |
| HUE049445T2 (hu) | Új kompozíciók | |
| BR112015002646A2 (pt) | composto e composição farmacêutica | |
| EP2914233A4 (en) | DENTAL COMPOSITIONS | |
| DK2811828T3 (da) | Adjuvanssammensætninger | |
| EP2837670A4 (en) | Fluorobiphenyl-containing composition |